enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. AstraZeneca's Farxiga cuts death risk in heart failure ... - AOL

   www.aol.com/news/astrazenecas-farxiga-cuts-death...

   AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...

3. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

4. Which 10 prescription drug prices are dropping in 2026 after ...

   www.aol.com/10-prescription-drug-prices-dropping...

   Farxiga. Farxiga from AstraZeneca AB is used to reduce the risks of diabetes, heart failure and chronic kidney disease. List price in 2023 for a 30-day supply was $556, new list price will be $178 ...

5. These are the drugs that are getting cheaper under new ... - AOL

   www.aol.com/drugs-getting-cheaper-under-medicare...

   Drugs used to treat heart disease, cancer, diabetes, blood clots and more are going to get cheaper, potentially saving money for million of people on Medicare. ... Jardiance, Januvia, and Farxiga ...

6. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment

7. Medicare can now negotiate prices on these drugs to help ...

   www.aol.com/medicare-now-negotiate-prices-drugs...

   - Jardiance (diabetes; heart failure) - Xarelto (prevention and treatment of blood clots; reduction of risk for patients with coronary or peripheral artery disease) - Januvia (diabetes)

8. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...

9. Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field

   www.aol.com/news/eli-lilly-boehringer-share...

   In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...